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Background The impact of pandemic H1N1 influenza (pH1N1) virus in pediatric cancer is uncertain. The objectives of this study were to characterize the clinical course of pH1N1 and identify factors associated with severe outcomes.
Methods We conducted a Canadian multicenter retrospective review of children with cancer and stem cell transplant (SCT) recipients who were diagnosed with laboratory-confirmed pH1N1 infection between May 1, 2009 and January 31, 2010.
Results We identified 100 (19 in wave 1 and 81 in wave 2) cases of pH1N1 infection. Median age was 8AE7 years. 71% had a hematologic malignancy, and 20% received SCT. Median duration of fever and illness was 2 and 12AE5 days, respectively. 51 (51AE5%) were hospitalized for a median of 5 days, with no deaths and only 1 requiring admission to the intensive care unit. Radiologically confirmed pneumonia was diagnosed in 10 (10%). Interruption of chemotherapy or conditioning occurred in 43 patients. In multivariable analyses, age <5 years (relative to ‡10 years) and neutropenia were associated with hospitalization while neutropenia was associated with pneumonia. Despite oseltamivir use in 89%, viral shedding was prolonged (median, 46 days) and often persisted after symptom resolution. However, an extended treatment course (>5 days) correlated with shortened duration of viral shedding (P = 0AE041).
Introduction
First detected in April of 2009, 1 the pandemic H1N1 influenza (pH1N1) virus rapidly spreads globally, triggering the first pandemic of the 21st century. By August 1, 2010, more than 214 countries reported laboratory-confirmed cases to the World Health Organization, including over 18 449 deaths. 2 Children with cancer and pediatric hematopoietic stem cell transplant (SCT) recipients comprise an important group of immunocompromised patients in whom prolonged viral shedding and serious influenza-associated morbidity are common. [3] [4] [5] [6] [7] [8] [9] [10] If pH1N1 substantially contributes to future influenza seasons as may be expected via antigenic drift, an understanding of its clinical course and severity in pediatric cancer patients in multiple geographic regions would help inform healthcare needs, provide information to facilitate decision-making regarding cancer treatment interruption, and identify early interventions to improve outcomes.
An analysis of pooled surveillance data on laboratoryconfirmed pH1N1 cases from 19 countries or administrative regions demonstrated that the odds ratio (OR) for death given hospitalization was >5 for immunocompromised patients, but did not determine ORs for subgroups of these patients. 11 Several studies of pH1N1 infection in pediatric cancer patients have yielded conflicting information, with some demonstrating a mild course, [12] [13] [14] [15] while a Brazilian study documented a high mortality rate among hospitalized cases. 16 Almost all of these studies were conducted at single centers, thus raising concerns about the generalizability of findings.
Consequently, we conducted a Canadian multicenter retrospective analysis of pH1N1 in pediatric cancer. Our objectives were to describe the clinical course and identify factors associated with severe outcomes of children with cancer or pediatric SCT recipients diagnosed with laboratory-confirmed pH1N1.
Methods

Patients and setting
We identified eligible cases through retrospective review of virology reports and health records from a base population of patients cared for by the Divisions of Haematology ⁄ Oncology at six Canadian pediatric referral centers (BC Children's Hospital, Vancouver; The Children's Hospital of Winnipeg, Winnipeg; Children's Hospital London Health Sciences Centre, London; McMaster Children's Hospital, Hamilton; The Hospital for Sick Children, Toronto; and Children's Hospital of Eastern Ontario, Ottawa).
Subjects eligible for study inclusion were (i) £18 years of age; (ii) receiving or about to receive chemotherapy for cancer or conditioning for SCT, or received treatment within the preceding 3 months (for chemotherapy patients), 6 months (for autologous SCT recipients), 2 years (for allogeneic SCT recipients), or receiving immunosuppressive therapy for graft-versus-host disease for those ‡2 years postallogeneic SCT; and (iii) diagnosed with pH1N1 infection by RT-PCR [using primers developed by the Centers for Disease Control and Prevention (CDC; Atlanta, GA) 17 or the National Microbiology Laboratory (NML; Public Health Agency of Canada, Winnipeg, MB), 18 or the Astra influenza Screen & Type (Astra Diagnostics, Hamburg, Germany) 19 ] of nasopharyngeal or flocked nasal mid-turbinate swabs between May 1, 2009 and January 6, 2010.
Case details abstracted from health records were reported on a standardized case report form. We collected patient demographics, underlying conditions, treatment information, clinical manifestations, pandemic H1N1 vaccination history, antiviral and antibiotic use, level of care required and influenza-related complications. All centers obtained research ethics board approval for the study.
Outcomes and definitions
North America experienced two waves of pH1N1 activity, peaking in most locations around June and October 2009. 20 Based on reporting of laboratory-confirmed pH1N1 hospitalized cases and deaths to the Public Health Agency of Canada, we defined wave 1 as the period prior to August 30, 2009. 21 Severe outcomes examined were hospitalization, radiologically confirmed pneumonia (defined as new pulmonary infiltrate on chest imaging associated with compatible clinical symptoms), intensive care unit (ICU) admission, need for mechanical ventilation, and mortality. Potential predictors of severe outcomes were identified from the literature or based on clinical experience and were defined a priori. Other complications of interest that developed between symptom onset and resolution were classified as respiratory complications, extra-respiratory complications or microbiologically confirmed infections. Extra-respiratory complications were further subcategorized into hematologic or nonhematologic complications. Hematologic complications of interest were neutropenia (absolute neutrophil count <500 ⁄ mm 3 ), lymphopenia (<500 ⁄ mm 3 ), and thrombocytopenia (<50 000 ⁄ mm 3 ). Non-hematologic complications specifically sought for included clinical diagnoses of sepsis (hypotension requiring fluid bolus or inotrope administration), pericarditis ⁄ myocarditis, myositis (elevated creatine phosphokinase), encephalitis, and hepatitis (aspartate aminotransferase or alanine aminotransferase > twice the upper limit of normal for age).
Obesity and underweight were covariates of interest and were examined for children at least 2 years of age. Obesity was defined as a body mass index (BMI) ‡ 95th percentile, and underweight was defined as BMI < 5th percentile based on the gender-and age-specific BMI reference from Centers for Disease Control and Prevention. 22 Children <2 years were not included in this analysis because of uncertainty in how to categorize children in this age-group.
Reflecting the recommendations of the Advisory Committee on Immunization Practices, 23 full vaccination with pH1N1 vaccine for children 6 months to <9 years was defined as receipt of two vaccine doses separated by at least 4 weeks with dose 2 received ‡14 days prior to illness onset. Those who received only one dose ‡14 days before illness onset were classified as partially vaccinated. Children aged 9-18 years were considered fully vaccinated with receipt of one vaccine dose ‡14 days prior to illness onset.
Statistical considerations
Standard descriptive statistics were used to summarize data on the study population. For all statistical testing, only the first pH1N1 episode was included in cases with multiple episodes within the same child because these episodes cannot be considered independent. Comparisons of data categorized by hospitalization versus no hospitalization, presence or absence of radiologically confirmed pneumonia, and pandemic wave (wave 2 versus 1) were made using the Mann-Whitney test for continuous variables and the v 2 or Fisher's exact test as appropriate for categorical variables. We performed univariate and multivariable linear or logistic regression, as appropriate, to adjust for potential confounding variables and to identify independent predictors of severe outcomes. We considered for the multivariable models all variables with P values <0AE1 in univariate analysis and retained in the final model all variables with an adjusted P-value <0AE05. All tests were two-sided, and a P value <0AE05 was considered statistically significant. Data were analyzed by spss statistical software (version 16AE0, SPSS Inc, Chicago, IL, USA).
Results
We identified a total of 102 episodes of laboratory-confirmed pH1N1 infection in 100 children with 100 unique first episodes. Unique episodes were distributed in two distinct waves: 19 in wave 1 prior to August 29, 2009 , and 81 in wave 2 from August 30, 2009 onward. In total, 51 ⁄ 99 were hospitalized (information missing in one child) and 10 ⁄ 100 were diagnosed with radiologically confirmed pneumonia.
Patient characteristics
Patient characteristics are illustrated in Table 1 , and results are stratified by whether children required hospitalization or was diagnosed with pneumonia. Median age was 8AE7 years, and males comprised 58AE0% of cases. Cancer diagnoses at the time of pH1N1 infection were leukemia (63AE0%), solid tumor (22AE0%), lymphoma (8AE0%), and brain tumor (7AE0%). Of these patients, 4 (4AE0%) had refractory disease, 12 (12AE0%) had relapsed disease, and 2 (2AE0%) had a secondary malignancy. 82 (82AE0%) were receiving chemotherapy around the time of pH1N1 infection, and 20 (20AE0%) had undergone either autologous (n = 8) or allogeneic (n = 12) SCT. Obesity was documented in 21 ⁄ 98 children ‡2 years, while two children were classified as underweight. Corticosteroids were part of anticancer therapy in 38 (38AE0%) patients. Of 18 children who received pH1N1 vaccine in the second wave, only one was fully vaccinated at the onset of pH1N1 illness. Clinical presentation, course, and management Table 2 illustrates symptoms at presentation of pH1N1 and during the illness course. The most commonly reported presenting symptoms were fever (84AE0%) and cough (80AE0%); 24AE0% had abdominal pain, nausea, vomiting, and ⁄ or diarrhea. Median interval between symptom onset and clinical encounter was 1 day [interquartile range (IQR), 0-2]. The treatment and clinical course of pH1N1 infection are presented in Tables 1 and 3 . Antiviral therapy was prescribed to most patients during the pandemic, with more frequent antiviral use in wave 2 than 1 (P = 0AE001). Overall, antiviral therapy was extended beyond the standard 5-day course for 17 (19AE5%) patients, 12 of whom received a 10-day course. Antibiotics were given in 56 (56AE0%) cases. Median duration of symptoms (defined as the interval between onset of any symptom and resolution of all symptoms) and that of fever was 12AE5 and 2 days, respectively.
We were able to determine the duration of shedding of pH1N1 virus for 35 patients, the median of which was 46 days. In the 22 patients for whom both duration of symptoms and viral shedding were available, 13 continued to shed virus after symptom resolution. The median duration of viral shedding did not differ significantly based on whether or not the patient was hospitalized (63 days [IQR, 14- (Table 4) . After multiple regression analysis, we found that an extended antiviral treatment course, but not wave 2, was significantly associated with shortened duration of viral shedding.
In terms of other complications, 2 experienced asthma exacerbation. Upper respiratory tract disease associated with pH1N1 infection were otitis media (n = 4), sinusitis (n = 2), and croup (n = 1). Hematologic abnormalities were neutropenia (n = 32), lymphopenia (n = 29), and thrombocytopenia (n = 17). Of the 11 patients classified as having a non-hematologic, extra-respiratory complication, nine had hepatitis. Microbiologically confirmed bacterial infection was documented in two cases (one coagulase-negative staphylococcus bacteremia and one Staphylococcus aureus cellulitis). Infection with a herpes group virus during the pH1N1 illness was reported in two patients (one herpes simplex virus and one Epstein-Barr virus), both managed as outpatients. Of the 82 patients scheduled for chemotherapy or conditioning for SCT, 43 had their chemotherapy or conditioning delayed (n = 23), modified (n = 5), or stopped ⁄ canceled (n = 11).
Severe outcomes of pH1N1
As previously described, 51 children were hospitalized and 10 had radiologically confirmed pneumonia (Table 3) . The median duration of hospitalization was 5 days (IQR, 3-13 days); for those with absolute neutrophil count (ANC) < 500 cells ⁄ mm 3 at pH1N1 diagnosis, it was 6 days (IQR, 4-11AE5 days). Overall, few patients developed critical illness. There was no mortality; one child was admitted to ICU for pneumonia requiring ‡60% supplemental oxygen and continuous positive airway pressure by face mask but not intubation or mechanical ventilation; and one child had pneumonia resulting in ‡60% supplemental oxygen therapy but did not require ICU admission. Table 5 displays univariate and multivariable analyses for predictors of pH1N1-associated hospitalization and pneumonia. In univariate analyses, children <5 years were more likely to be hospitalized (P = 0AE003) and those aged 5-9 years trended toward being more likely to have pneumonia (P = 0AE063), compared to children ‡10 years. Neutropenia at pH1N1 diagnosis was associated with hospitalization (P < 0AE001) and pneumonia (P = 0AE005), as was neutropenia detected at any time during the illness (P < 0AE001 and P = 0AE015, respectively). We did not collect data on lymphopenia at pH1N1 diagnosis, but lymphopenia detected at any time during the illness was not associated with hospitalization or pneumonia. Multiple logistic regression revealed that age category and neutropenia (both at diagnosis and during the illness) were significant independent predictors of hospitalization, with children <5 years at highest risk. Neutropenia, but not age, was a significant predictor of pneumonia in multiple logistic regression analysis. The models that included age and neutropenia at diagnosis fit the observed data well (Hosmer-Lemeshow P = 0AE955 and 0AE778 for hospitalization and pneumonia, respectively) and discriminated well between those who were and were not hospitalized [c-index, 0AE767 (95% CI, 0AE670-0AE864)] as well as between children with and without pneumonia [c-index, 0AE839 (95% CI, 0AE735-0AE942)].
Discussion
This study resulted in several important observations. First, pH1N1 infection was uncomplicated in most children with cancer although commonly interrupted anticancer therapy. Second, neutropenia was an important predictor of hospitalization as well as pneumonia. Third, antiviral prescription increased significantly during wave 2 of the pandemic. Finally, prolonged viral shedding often persisted after symptom resolution, and an extended antiviral treatment In our cohort, 51AE5% of patients were hospitalized and 10% developed lower respiratory tract infection. Although only one patient was admitted to the ICU and none died, 52AE4% of those scheduled for chemotherapy or conditioning had treatment modified or held. These results are comparable to those of modest-sized case series of pediatric cancer patients from Italy, 13 Texas, 12 Jordan, 14 and Turkey. 15 In contrast, a Brazilian study found that 8 ⁄ 14 pediatric cancer patients hospitalized with pH1N1 required ICU admission and ventilator support. This is consistent with the high rate of severe complications from pH1N1 infection in the general Brazilian population. 16 Potential explanations for the discrepant findings of this study include increased predisposition to severe pH1N1 infection in the Brazilian population owing to host genetic and ⁄ or socioeconomic factors.
Several factors may contribute to the generally favorable outcome of pH1N1 infection in cancer patients. First, parents of children with cancer are likely to seek prompt medical attention in the presence of fever, resulting in early diagnosis and antiviral treatment. A meta-analysis of 11 randomized controlled trials (RCTs) showed that oseltamivir treatment was associated with a reduced risk of lower respiratory tract complications in adolescents and adults with flu symptoms. 24 A recent RCT demonstrated that early antiviral treatment in children aged 1-3 years reduced illness duration and incidence of otitis media. 25 Second, increased cytokine and chemokine plasma levels have been shown to be markers of critical illness with pH1N1 infection, suggesting that immunopathology may contribute to disease severity. 26, 27 It is possible that the relatively benign course of illness in children with cancer is partly related to decreased cytokine and chemokine production related to immune suppression. Third, high levels of cross-reacting but non-neutralizing antibodies that result from previous seasonal influenza exposures, leading to immune complexmediated pulmonary disease, have been advanced as a novel biological mechanism of severe cases of pH1N1 in middle-aged individuals. 28 Pediatric cancer and SCT patients have impaired serum antibody responses to both seasonal influenza vaccination and natural infection and would, therefore, likely be protected from this mechanism of severe pH1N1 disease. Finally, concurrent bacterial infection has been documented in 29% of lung tissue specimens from fatal human cases of pH1N1. 29 Neutropenia was an independent predictor of pneumonia in our study, and neutropenia, in association with fever, would trigger hospitalization and broad-spectrum antibiotic therapy resulting in early treatment of established or subclinical bacterial lower respiratory tract infection along with more intensive supportive therapy.
It is possible that neutropenia was merely a surrogate for profound lymphopenia that has been shown to correlate with the risk of influenza-associated lower respiratory tract infection 30, 31 and that the lack of association of concurrent lymphopenia with pneumonia in our study reflected a higher cut-off point compared to previous studies demonstrating association (<500 ⁄ mm 3 versus <100-200 ⁄ mm 3 ). 30, 31 More detailed analysis of ANC and absolute lymphocyte count (ALC) in relation to the pattern of radiographic changes (viral versus bacterial) in future studies could provide further insight. In addition to neutropenia, our study indicated that younger age (particularly those <5 years) was associated with hospitalization for pH1N1 infection. This is consistent with reported rates of pH1N1-associated hospitalization in the general pediatric population, being highest for children <5 years and especially for those <12 months. 32 Morbid obesity has been associated with hospitalization and death from pH1N1 infection in adults. 33, 34 In contrast, in children, hospitalization appears to be associated with being underweight, and death has not been associated with BMI category. 33 Consistent with this observation was the relatively uncomplicated clinical course of our cohort, which included a large number of obese but only two underweight children.
While antiviral treatment was prescribed to most patients in our study, its use was significantly less frequent during wave 1, when only 63AE2% were treated with oseltamivir. This occurred despite the existence of antiviral therapy guidelines predating the pandemic that recommended treatment for children at high risk of severe influenza, including those with cancer. 35, 36 The gap in adherence to such guidelines during wave 1 suggests that either guideline dissemination was suboptimal or that clinicians were further risk-stratifying patients for antiviral therapy. The increased use of antivirals during wave 2 in our cohort might have reflected emergence of reports in the literature and media of severe pH1N1 cases.
Our study demonstrated that cancer and SCT patients had prolonged viral shedding, which has also been observed in studies of cancer patients with seasonal influenza. 37 A recent report of cancer patients hospitalized with pH1N1 also documented prolonged excretion of virus, in which 5 ⁄ 10 mechanically ventilated patients shed virus for ‡11 days. 16 Given that severe respiratory illness has also been associated with delayed pH1N1 clearance, 38 the authors acknowledged that they could not determine whether the persistent pH1N1 shedding in their study was attributed to the severity of pH1N1 disease, the underlying immunocompromised state, or both. Our data indicate that an immunocompromised state is an important contributor to prolonged excretion of pH1N1 virus. Therefore, pH1N1-infected cancer patients could potentially serve as mixing vessels, when infected with seasonal influenza viruses, for genetic reassortment and generation of a more virulent influenza subtype. 39 Another important observation was that viral shedding often extended far beyond the symptomatic period. This finding may have important infection control implications. While isolation of the symptomatic patient is clear, the role of asymptomatic viral shedding in transmission is less well studied and recommendations for isolation of these patients are variable. 40, 41 If asymptomatic shedding can result in the spread of influenza, then it would be important to practice strict infection control practices until laboratory confirmation of viral clearance in hospitalized patients and for outpatients returning to the ambulatory clinic for continuing care regardless of symptoms.
We also found that treatment with an extended course of oseltamivir was associated with a shorter duration of viral shedding. While early use of oseltamivir has been associated with reduction in days of viral shedding, 38 we are not aware of previous data demonstrating a correlation between length of antiviral treatment and duration of viral shedding. Some experts have advocated a 10-day course as the standard duration for immunocompromised patients 42 although the Advisory Committee on Immunization Practices merely states that 'longer treatment regimens might be necessary in severely ill hospitalized patients or persons with immunosuppression'. 43 These factors, along with the generally mild clinical course, may have accounted for the 
ORs generated by logistic regression. ANC, absolutely neutrophil count; ALC, absolute lymphocyte count; CI, confidence interval; OR, odds ratio. * ORs and P values displayed in multivariable models are those generated with inclusion of ANC <500 ⁄ mm 3 at pH1N1 diagnosis as a predictor Limitations of the study include its retrospective design and inability to calculate population-based rates. Based on its retrospective nature, our ability to determine whether the hematologic complications were attributable to influenza infection or to chemotherapy was limited, and our results may be affected by unobserved confounders or insufficient adjustment for observed confounders. The precision in our estimate of the duration of viral shedding may have been limited given that follow-up influenza testing was performed at the clinicians' discretion. The extent of prolonged viral shedding may have been overestimated by overrepresentation of serial sampling in patients with longer courses. We did not capture data on the duration of individual symptoms and therefore were not able to identify those which could potentially be used to guide optimal retesting and treatment. Although larger than previous studies of pediatric cancer and SCT patients, our sample size was still relatively small. Some of our metrics of influenza severity such as hospitalization, length of hospital stay, and ICU admission may be influenced by variation in clinical practice across centers as well as non-medical factors such as publicity surrounding the pandemic and bed availability.
In conclusion, pH1N1 infection was associated with an uncomplicated course in most pediatric cancer and SCT patients but commonly altered scheduling of chemotherapy or transplant conditioning. Although neutropenia was an independent predictor of radiologically confirmed pneumonia, it is unclear whether it can be used as a criterion separate from lymphopenia for decision-making regarding cancer treatment modification given the limitations in our analysis of lymphopenia as a risk factor. Despite the uncomplicated course in most, viral shedding was prolonged and often continued after symptom resolution. Prospective studies evaluating the effects of extended antiviral treatment on viral shedding in cancer and SCT patients, while addressing the limitations in this study, could have an important bearing on infection control practices and treatment guidelines.
